Home Categories API Nilotinib (AMN-107)
A6206212

Nilotinib (AMN-107) , ≥99% , 641571-10-0

CAS NO.:641571-10-0

Empirical Formula: C28H22F3N7O

Molecular Weight: 529.52

MDL number: MFCD09833716

EINECS: 700-544-5

Pack Size Price Stock Quantity
25MG RMB63.20 In Stock
100MG RMB119.20 In Stock
250MG RMB216.80 In Stock
1g RMB544.00 In Stock
5g RMB2228.00 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 231-233 °C
Density  1.36
storage temp.  -20°C Freezer
solubility  Soluble in DMSO (up to 50 mg/ml)
form  Beige powder.
color  Off-white
Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChIKey HHZIURLSWUIHRB-UHFFFAOYSA-N
SMILES N1(C=C(C)N=C1)C1C=C(C=C(C=1)NC(=O)C1C=CC(C)=C(NC2=NC=CC(C3=CC=CN=C3)=N2)C=1)C(F)(F)F
CAS DataBase Reference 641571-10-0(CAS DataBase Reference)

Description and Uses

Chronic myeloid leukemia (CML), a hematological stem-cell disorder, is definitively diagnosed by the detection of the Philadelphia chromosome, a truncated version of chromosome 22 resulting from the reciprocal translocation of chromosomes 9 and 22 induced by a single mutagenic event. The consequence is the juxtaposition of two genes creating a fusion gene BCR-ABL. This gene leads to the translation of a fusion protein with increased tyrosine kinase activity that contributes to the pathogenesis of CML. Targeting the BCR-ABL protein has led to the successful intervention of the disease. Now established as first-line therapy for CML, imatinib was the first selective tyrosine kinase inhibitor of BCR-ABL. Since imatinib only binds to an inactive conformation of the ABL kinase portion, the conformational restrictions contribute to its selectivity.

Nilotinib, an orally active signal transduction inhibitor that selectively inhibits the tyrosine kinase Bcr-Abl, was discovered and developed by Norvartis and was launched for the treatment of chronic myeloid leukemia (CML) in patients with Philadelphia chromosome-positive (Ph+) disease who are resistant or intolerant to imatinib mesilate. Additional clinical trials are currently underway for the treatment of acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GISTs).

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H315-H319-H335
Precautionary statements  P261-P305+P351+P338
HS Code  29335990
Hazardous Substances Data 641571-10-0(Hazardous Substances Data)

RELATED PRODUCTS